QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.125831v1 322/3/1221    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Windass, A. S. Articles by Brown, C. D. A. Search for Related Content PubMed PubMed Citation Articles by Windass, A. S. Articles by Brown, C. D. A.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

The Contribution of Organic Anion Transporters OAT1 and OAT3 to the Renal Uptake of Rosuvastatin

Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (A.S.W., S.L., C.D.A.B.); and DMPK, AstraZeneca LP, Wilmington, Delaware (Y.W.)

Rosuvastatin is a potent inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase and has been shown to be highly effective in reducing low-density lipoprotein cholesterol. Clinical trials have demonstrated that renal excretion and, in particular, tubular secretion, plays a role in rosuvastatin clearance. The aim of this study was to determine the involvement of the basolateral organic anion transporters, OAT1 and OAT3, in the renal uptake of rosuvastatin. Expression of human (h) OAT3 in Xenopus oocytes significantly increased the uptake of rosuvastatin above control levels (K_m = 7.4 µM). In contrast hOAT1 did not mediate rosuvastatin uptake. Furthermore, hOAT3-mediated estrone-3-sulfate uptake could be inhibited, with a rank order of potency, by atorvastatin, rosuvastatin, simvastatin, and pravastatin, whereas hOAT1-mediated PAH uptake was only significantly inhibited by simvastatin. To estimate the contribution of hOAT3 to the overall renal uptake of rosuvastatin, a series of experiments were conducted using rat kidney slices. Rosuvastatin uptake in rat renal slices was abolished in the presence of the rat (r) Oat3-specific inhibitor benzylpenicillin, suggesting that rOat3 is responsible for the majority of rosuvastatin uptake across the basolateral membrane in rat kidney. From these findings, we can suggest that hOAT3 contributes to the renal uptake of rosuvastatin in humans.

Address correspondence to: Dr. Colin D. A. Brown, Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. E-mail: c.d.a.brown{at}ncl.ac.uk

This article has been cited by other articles:

				T. Zhu, W. M. Awni, B. Hosmane, M. T. Kelly, D. J. Sleep, J. C. Stolzenbach, K. Wan, T. O. Chira, and R. S. Pradhan ABT-335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans J. Clin. Pharmacol., January 1, 2009; 49(1): 63 - 71. [Abstract] [Full Text] [PDF]

				A. Verhulst, R. Sayer, M. E. De Broe, P. C. D'Haese, and C. D. A. Brown Human Proximal Tubular Epithelium Actively Secretes but Does Not Retain Rosuvastatin Mol. Pharmacol., October 1, 2008; 74(4): 1084 - 1091. [Abstract] [Full Text] [PDF]